Rab25 expression predicts poor prognosis in clear cell renal cell carcinoma

Rab25 has been implicated in a number of types of cancer. However, its expression status and clinical implications in clear cell renal cell carcinoma (ccRCC) remain to be investigated. The purpose of this study was to investigate the significance of Rab25 status in patients with ccRCC. Rab25 expression was determined by western blot analysis in 30 fresh ccRCC samples. Immunohistochemistry was performed on the ccRCC samples and paired adjacent noncancerous tissues from 107 patients with ccRCC who had undergone surgery. The prognostic role and correlations with other clinicopathological factors were evaluated. Rab25 expression was upregulated in ccRCC tissues compared with that in paired adjacent noncancerous tissues. A high expression of Rab25 protein was significantly correlated with the primary tumor stage; lymph node metastasis; distant metastasis; tumor, node and metastasis stage and histological grade. A Kaplan-Meier survival analysis by log-rank test demonstrated that elevated Rab25 expression predicted lower overall survival time in patients with ccRCC. Notably, multivariate analyses revealed that expression of Rab25 was an independent prognostic factor in ccRCC (hazard ratio, 3.43; 95% confidence interval, 1.13-10.38; P=0.023). In conclusion, Rab25 is a potential prognostic biomarker in ccRCC.